Point: Antibiotic therapy is not the answer for patients with persisting symptoms attributable to Lyme disease

Clinical Infectious Diseases

Volumn 45, Issue 2, 2007, Pages 143-148

  Auwaerter, Paul G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; DOXYCYCLINE; PLACEBO; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BONE PAIN; BORRELIA BURGDORFERI; CHRONIC DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; FATIGUE; HUMAN; LYME DISEASE; MYALGIA; PERSISTENT INFECTION; PRIORITY JOURNAL; SYMPTOM; SYNDROME DELINEATION; TREATMENT DURATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; FOLLOW UP; HOSPITALIZATION; ISOLATION AND PURIFICATION; MALE; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BORRELIA BURGDORFERI; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYME DISEASE; MALE; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34447102148     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/518854     Document Type: Conference Paper

References (62)

1. Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clin Invest 2004; 113:1093-101.
2. Lyme disease - United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2004; 53:365-9.
3. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089-134.
4. Stricker RB, Lautin A, Burrascano JJ. Lyme disease: point/counterpoint. Expert Rev Anti Infect Ther 2005; 3:155-65.
5. Cameron D, Gaito A, Harris N, et al. Evidence-based guidelines for the management of Lyme disease. Expert Rev Anti Infect Ther 2004; 2:S1-13.
6. Klempner MS. Controlled trials of antibiotic treatment in patients with post-treatment chronic Lyme disease. Vector Borne Zoonotic Dis 2002; 2:255-63.
7. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Morb Mortal Wkly Rep 1997; 46:1-51.
8. Wormser GP, Nadelman RB, Dattwyler RJ, et al. Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin Infect Dis 2000; 31(Suppl 1):1-14.
9. Stricker R, ILADS. ILADS demands retraction of IDSA Lyme guidelines, 2006. Available at: http://www.ilads.org/files/press_release_10_25 _06. pdf.
10. Steere AC, Malawista SE, Newman JH, Spieler PN, Bartenhagen NH. Antibiotic therapy in Lyme disease. Ann Intern Med 1980; 93:1-8.
11. Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992; 117:273-80.
12. Luger SW, Paparone P, Wormser GP, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 1995; 39:661-7.
13. Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138:697-704.
14. Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 2006; 54: 3079-86.
15. Steere AC, Klitz W, Drouin EE, et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med 2006; 203:961-71.
16. Nowakowski J, Nadelman RB, Sell R, et al. Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med 2003; 115: 91-6.
17. Steere AC, Hutchinson GJ, Rahn DW, et al. Treatment of the early manifestations of Lyme disease. Ann Intern Med 1983; 99:22-6.
18. Dattwyler RJ, Wormser GP, Rush TJ, et al. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien Klin Wochenschr 2005; 117:393-7.
19. Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. JAMA 1993; 269:1812-6.
20. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995; 44:590-1.
21. Auwaerter PG, Aucott J, Dumler JS. Lyme borreliosis (Lyme disease): molecular and cellular pathobiology and prospects for prevention, diagnosis and treatment. Expert Rev Mol Med 2004; 2004:1-22.
22. Centers for Disease Control and Prevention. Notice to readers: caution regarding testing for Lyme disease. MMWR Morb Mortal Wkly Rep 2005; 54:125.
23. The Iowa Persian Gulf Study Group. Self-reported illness and health status among Gulf War veterans: a population-based study. JAMA 1997; 277:238-45.
24. Buchwald D, Umali P, Umali J, Kith P, Pearlman T, Komaroff AL. Chronic fatigue and the chronic fatigue syndrome: prevalence in a Pacific Northwest health care system. Ann Intern Med 1995; 123:81-8.
25. Wessely S. Chronic fatigue: symptom and syndrome. Ann Intern Med 2001; 134:838-43.
26. Centers for Disease Control and Prevention. Monitoring progress in arthritis management - United States and 25 states, 2003. MMWR Morb Mortal Wkly Rep 2005; 54:484-8.
27. Croft P, Rigby AS, Boswell R, Scholium J, Silman A. The prevalence of chronic widespread pain in the general population. J Rheumatol 1993; 20:710-3.
28. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38:19-28.
29. American College of Rheumatology, Council of the Infectious Diseases Society of America. Appropriateness of parenteral antibiotic treatment for patients with presumed Lyme disease: a joint statement of the American College of Rheumatology and the Council of the Infectious Diseases Society of America. Ann Intern Med 1993; 119:518.
30. Nichol G, Dennis DT, Steere AC, et al. Test-treatment strategies for patients suspected of having Lyme disease: a cost-effectiveness analysis. Ann Intern Med 1998; 128:37-48.
31. Barsky AJ, Borus JF. Functional somatic syndromes. Ann Intern Med 1999; 130:910-21.
32. Weissmann G. "Chronic Lyme" and other medically unexplained syndromes. Faseb J 2007; 21:299-301.
33. Katz BZ. Update on chronic fatigue syndrome and Epstein-Barr virus. Pediatr Ann 2002; 31:741-4.
34. Renfro L, Feder HM Jr, Lane TJ, Manu P, Matthews DA. Yeast connection among 100 patients with chronic fatigue. Am J Med 1989; 86: 165-8.
35. Appel S, Chapman J, Shoenfeld Y. Infection and vaccination in chronic fatigue syndrome: myth or reality? Autoimmunity 2007; 40:48-53.
36. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345:85-92.
37. Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003; 60:1923-30.
38. Donta ST. Macrolide therapy of chronic Lyme disease. Med Sci Monit 2003; 9:PI136-42.
39. Donta ST. Tetracycline therapy for chronic Lyme disease. Clin Infect Dis 1997; 25(Suppl 1):S52-6.
40. Fallon BA, Tager F, Fein L, et al. Repeated antibiotic treatment in chronic Lyme disease. J Spirochetal Tickborne Dis 1999; 6:94-102.
41. Bannwarth B. Antimicrobial effects of antiinflammatory drugs, anti-inflammatory effects of antimicrobial drugs. Rev Rhum Engl Ed 1999; 66:73S-6S.
42. Donta ST, Engel CC Jr, Collins JF, et al. Benefits and harms of doxycycline treatment for Gulf War veterans' illnesses: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004; 141:85-94.
43. Berger BW, Johnson RC, Kodner C, Coleman L. Failure of Borrelia burgdorferi to survive in the skin of patients with antibiotic-treated Lyme disease. J Am Acad Dermatol 1992; 27:34-7.
44. Nadelman RB, Nowakowski J, Forseter G, et al. Failure to isolate Borrelia burgdorferi after antimicrobial therapy in culture-documented Lyme borreliosis associated with erythema migrans: report of a prospective study. Am J Med 1993; 94:583-8.
45. Alban PS, Johnson PW, Nelson DR. Serum-starvation-induced changes in protein synthesis and morphology of Borrelia burgdorferi. Microbiology 2000; 146:119-27.
46. Craig-Mylius K, Weber GF, Coburn J, Glickstein L. Borrelia burgdorferi, an extracellular pathogen, circumvents osteopontin in inducing an inflammatory cytokine response. J Leukoc Biol 2005; 77:710-8.
47. Pal U, Fikrig E. Adaptation of Borrelia burgdorferi in the vector and vertebrate host. Microbes Infect 2003; 5:659-66.
48. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. MMWR Morb Mortal Wkly Rep 2006; 55:1-94.
49. Stoner BP. Current controversies in the management of adult syphilis. Clin Infect Dis 2007; 44(Suppl 3):S130-46.
50. Hunfeld KP, Ruzic-Sabljic E, Norris DE, Kraiczy P, Strle F. In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob Agents Chemother 2005; 49:1294-301.
51. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283:2537-45.
52. Siegman-Igra Y, Kaufman O, Keysary A, Rzotkiewicz S, Shalit I. Q fever endocarditis in Israel and a worldwide review. Scand J Infect Dis 1997; 29:41-9.
53. Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ 2006; 333:575.
54. Berelowitz GJ, Burgess AP, Thanabalasingham T, Murray-Lyon IM, Wright DJ. Post-hepatitis syndrome revisited. J Viral Hepat 1995; 2: 133-8.
55. Sacks N, Van Rensburg AJ. Clinical aspects of chronic brucellosis. S Afr Med J 1976; 50:725-8.
56. Kerr JR, Bracewell J, Laing I, et al. Chronic fatigue syndrome and arthralgia following parvovirus B19 infection. J Rheumatol 2002; 29: 595-602.
57. Rosene KA, Copass MK, Kastner LS, Nolan CM, Eschenbach DA. Persistent neuropsychological sequelae of toxic shock syndrome. Ann Intern Med 1982; 96:865-70.
58. Vernon SD, Nicholson A, Rajeevan M, et al. Correlation of psychoneuroendocrine-immune (PNI) gene expression with symptoms of acute infectious mononucleosis. Brain Res 2006; 1068:1-6.
59. Vernon SD, Whistler T, Cameron B, Hickie IB, Reeves WC, Lloyd A. Preliminary evidence of mitochondrial dysfunction associated with post-infective fatigue after acute infection with Epstein Barr virus. BMC Infect Dis 2006; 6:15.
60. Ettestad PJ, Campbell GL, Welbel SF, et al. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis 1995; 171: 356-61.
61. Patel R, Grogg KL, Edwards WD, Wright AJ, Schwenk NM. Death from inappropriate therapy for Lyme disease. Clin Infect Dis 2000; 31: 1107-9.
62. Nadelman RB, Arlin Z, Wormser GP. Life-threatening complications of empiric ceftriaxone therapy for 'seronegative Lyme disease.' South Med J 1991; 84:1263-5.